|
1
|
van Meerbeeck JP, Fennell DA and De
Ruysscher DK: Small-Cell lung cancer. Lancet. 378:1741–1755. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Amini A, Byers LA, Welsh JW and Komaki RU:
Progress in the management of limited-stage small cell lung cancer.
Cancer. 120:790–798. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kiani A, Khosravi A, Moghaddam AS, Jabbari
H and Fakhri M: Long-Term survival of a small cell lung cancer
patient with proper endobronchial management. Pneumologia.
61:245–248. 2012.PubMed/NCBI
|
|
4
|
Poola I and Graziano SL: Expression of
neuron-specific enolase, chromogranin A, synaptophysin and Leu-7 in
lung cancer cell lines. J Exp Clin Cancer Res. 17:165–173.
1998.PubMed/NCBI
|
|
5
|
Yang X, Wang D, Yang Z, Qing Y, Zhang Z,
Wang G, Yang Z and Wang Z: CEA is an independent prognostic
indicator that is associated with reduced survival and liver
metastases in SCLC. Cell Biochem Biophys. 59:113–119. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Molina R, Auge JM, Escudero JM, Marrades
R, Viñolas N, Carcereny E, Ramirez J and Filella X: Mucins CA 125,
CA 19.9, CA 15.3 and TAG-72.3 as tumor markers in patients with
lung cancer: Comparison with CYFRA 21-1, CEA, SCC and NSE. Tumour
Biol. 29:371–380. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Winther B, Moi P, Paus E and Reubsaet JL:
Targeted determination of the early stage SCLC specific biomarker
pro-gastrin-releasing peptide (ProGRP) at clinical concentration
levels in human serum using LC-MS. J Sep Sci. 30:2638–2646. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nakai K, Kikuchi M, Fujimoto K, Kaneko Y,
Omori S, Nakai K and Suwabe A: Serum levels of cystatin C in
patients with malignancy. Clin Exp Nephrol. 12:132–139. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kos J, Krasovec M, Cimerman N, Nielsen HJ,
Christensen IJ and Brünner N: Cysteine proteinase inhibitors stefin
A, stefin B, and cystatin C in sera from patients with colorectal
cancer: Relation to prognosis. Clin Cancer Res. 6:505–511.
2000.PubMed/NCBI
|
|
10
|
Ames BN, Cathcart R, Schwiers E and
Hochstein P: Uric acid provides an antioxidant defense in humans
against oxidant- and radical-caused aging and cancer: A hypothesis.
Proc Natl Acad Sci USA. 78:6858–6862. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vona-Davis L, Howard-McNatt M and Rose DP:
Adiposity, type 2 diabetes and the metabolic syndrome in breast
cancer. Obes Rev. 8:395–408. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dang CV and Lewis BC: Role of oncogenic
transcription factor c-myc in cell cycle regulation, apoptosis and
metabolism. J Biomed Sci. 4:269–278. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Naumnik W, Niklińska W, Ossolińska M and
Chyczewska E: Serum cathepsin K and cystatin C concentration in
patients with advanced non-small-cell lung cancer during
chemotherapy. Folia Histochem Cytobiol. 47:207–213. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Parks SK, Chiche J and Pouysségur J:
Disrupting proton dynamics and energy metabolism for cancer
therapy. Nat Rev Cancer. 13:611–623. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Micke P, Faldum A, Metz T, Beeh KM,
Bittinger F, Hengstler JG and Buhl R: Staging small cell lung
cancer: Veterans administration lung study group versus
international association for the study of lung cancer-what limits
limited disease? Lung Cancer. 37:271–276. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ghaemi-Oskouie F and Shi Y: The role of
uric acid as an endogenous danger signal in immunity and
inflammation. Curr Rheumatol Rep. 13:160–166. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fantin VR, St-Pierre J and Leder P:
Attenuation of LDH-A expression uncovers a link between glycolysis,
mitochondrial physiology, and tumor maintenance. Cancer Cell.
9:425–434. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lewis BC, Shim H, Li Q, Wu CS, Lee LA,
Maity A and Dang CV: Identification of putative c-myc-responsive
genes: Characterization of rcl, a novel growth-related gene. Mol
Cell Biol. 17:4967–4978. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shim H, Dolde C, Lewis BC, Wu CS, Dang G,
Jungmann RA, Dalla-Favera R and Dang CV: C-Myc transactivation of
LDH-A: Implications for tumor metabolism and growth. Proc Natl Acad
Sci USA. 94:6658–6663. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Koukourakis MI, Giatromanolaki A, Sivridis
E, Gatter KC, Trarbach T, Folprecht G, Shi MM, Lebwohl D, Jalava T,
Laurent D, et al: Prognostic and predictive role of lactate
dehydrogenase 5 expression in colorectal cancer patients treated
with PTK787/ZK 222584 (vatalanib) antiangiogenic therapy. Clin
Cancer Res. 17:4892–4900. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Turen S, Ozyar E, Altundag K, Gullu I and
Atahan IL: Serum lactate dehydrogenase level is a prognostic factor
in patients with locoregionally advanced nasopharyngeal carcinoma
treated with chemoradiotherapy. Cancer Invest. 25:315–321. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jin Y, Ye X, Shao L, Lin BC, He CX, Zhang
BB and Zhang YP: Serum lactic dehydrogenase strongly predicts
survival in metastatic nasopharyngeal carcinoma treated with
palliative chemotherapy. Eur J Cancer. 49:1619–1626. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Brown JE, Cook RJ, Lipton A and Coleman
RE: Serum lactate dehydrogenase is prognostic for survival in
patients with bone metastases from breast cancer: A retrospective
analysis in bisphosphonate-treated patients. Clin Cancer Res.
18:6348–6355. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Halabi S, Small EJ, Kantoff PW, Kattan MW,
Kaplan EB, Dawson NA, Levine EG, Blumenstein BA and Vogelzang NJ:
Prognostic model for predicting survival in men with
hormone-refractory metastatic prostate cancer. J Clin Oncol.
21:1232–1237. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
von Eyben FE, Madsen EL, Liu F, Amato R
and Fritsche H: Serum lactate dehydrogenase isoenzyme 1 as a
prognostic predictor for metastatic testicular germ cell tumours.
Br J Cancer. 83:1256–1259. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gerlinger M, Wilson P, Powles T and
Shamash J: Elevated LDH predicts poor outcome of recurrent germ
cell tumours treated with dose dense chemotherapy. Eur J Cancer.
46:2913–2918. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Egberts F, Kotthoff EM, Gerdes S, Egberts
JH, Weichenthal M and Hauschild A: Comparative study of YKL-40,
S-100B and LDH as monitoring tools for stage IV melanoma. Eur J
Cancer. 48:695–702. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Agarwala SS, Keilholz U, Gilles E,
Bedikian AY, Wu J, Kay R, Stein CA, Itri LM, Suciu S and Eggermont
AM: LDH correlation with survival in advanced melanoma from two
large, randomised trials (Oblimersen GM301 and EORTC 18951). Eur J
Cancer. 45:1807–1814. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Seagroves TN, Ryan HE, Lu H, Wouters BG,
Knapp M, Thibault P, Laderoute K and Johnson RS: Transcription
factor HIF-1 is a necessary mediator of the pasteur effect in
mammalian cells. Mol Cell Biol. 21:3436–3444. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Schofield CJ and Ratcliffe PJ: Oxygen
sensing by HIF hydroxylases. Nat Rev Mol Cell Biol. 5:343–354.
2004. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ostergaard L, Tietze A, Nielsen T, Drasbek
KR, Mouridsen K, Jespersen SN and Horsman MR: The relationship
between tumor blood flow, angiogenesis, tumor hypoxia, and aerobic
glycolysis. Cancer Res. 73:5618–5624. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ryberg M, Nielsen D, Osterlind K,
Skovsgaard T and Dombernowsky P: Prognostic factors and long-term
survival in 585 patients with metastatic breast cancer treated with
epirubicin-based chemotherapy. Ann Oncol. 12:81–87. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Brizel DM, Schroeder T, Scher RL, Walenta
S, Clough RW, Dewhirst MW and Mueller-Klieser W: Elevated tumor
lactate concentrations predict for an increased risk of metastases
in head-and-neck cancer. Int J Radiat Oncol Biol Physics.
51:349–353. 2001. View Article : Google Scholar
|
|
34
|
Ervin H and Cox JL: Late stage inhibition
of hematogenous melanoma metastasis by cystatin C over-expression.
Cancer Cell Int. 5:142005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sevier CS and Kaiser CA: Formation and
transfer of disulphide bonds in living cells. Nat Rev Mol Cell
Biol. 3:836–847. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Choi SW and Mason JB: Folate and
carcinogenesis: An integrated scheme. J Nutr. 130:129–132. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Saleh Y, Sebzda T, Warwas M, Kopec W,
Ziólkowska J and Siewinski M: Expression of cystatin C in clinical
human colorectal cancer tissues. J Exp Ther Oncol. 5:49–53.
2005.PubMed/NCBI
|
|
38
|
Zhang X, Hou Y, Niu Z, Li W, Meng X, Zhang
N and Yang S: Clinical significance of detection of cathepsin X and
cystatin C in the sera of patients with lung cancer. Zhongguo Fei
Ai Za Zhi. 16:411–416. 2013.(In Chinese). PubMed/NCBI
|
|
39
|
Hammarsten J, Damber JE, Peeker R,
Mellström D and Högstedt B: A higher prediagnostic insulin level is
a prospective risk factor for incident prostate cancer. Cancer
Epidemiol. 34:574–579. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bjorge T, Lukanova A, Jonsson H, Tretli S,
Ulmer H, Manjer J, Stocks T, Selmer R, Nagel G, Almquist M, et al:
Metabolic syndrome and breast cancer in the me-can (metabolic
syndrome and cancer) project. Cancer Epidemiol Biomarkers Prev.
19:1737–1745. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Rose DP, Haffner SM and Baillargeon J:
Adiposity, the metabolic syndrome, and breast cancer in
African-American and white American women. Endocr Rev. 28:763–777.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Giovannucci E: Metabolic syndrome,
hyperinsulinemia, and colon cancer: A review. Am J Clin Nutr.
86:s836–s842. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Siddiqui AA: Metabolic syndrome and its
association with colorectal cancer: A review. Am J Med Sci.
341:227–231. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Linder N, Butzow R, Lassus H, Lundin M and
Lundin J: Decreased xanthine oxidoreductase (XOR) is associated
with a worse prognosis in patients with serous ovarian carcinoma.
Gynecol Oncol. 124:311–318. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Herrmann MK, Bloch E, Overbeck T, Koerber
W, Wolff HA, Hille A, Vorwerk H, Hess CF, Muller M, Christiansen H
and Pradier O: Mediastinal radiotherapy after multidrug
chemotherapy and prophylactic cranial irradiation in patients with
SCLC-treatment results after long-term follow-up and literature
overview. Cancer Radiother. 15:81–88. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Buyse M, Thirion P, Carlson RW,
Burzykowski T, Molenberghs G and Piedbois P; Mata-analysis Group in
Cancer, : Re: A model to select chemotherapy regimens for phase III
trials for extensive-stage small-cell lung cancer. J Natl Cancer
Inst. 93:399–401. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Abdelwahab S, Abdulla H, Azmy A,
Abdelfatah A, Abdel-Aziz H, Margerges M, Riad A, Sharma V and
Dwedar I: Integration of irinotecan and cisplatin with early
concurrent conventional radiotherapy for limited-disease SCLC
(LD-SCLC). Int J Clin Oncol. 14:230–236. 2009. View Article : Google Scholar : PubMed/NCBI
|
